---
title: "Buy Rating Reiterated on Amylyx as Avexitide Progress and Cash Runway Support Upside vs. Unchanged $24 Price Target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285621003.md"
description: "Rami Katkhuda from LifeSci Capital reiterated a Buy rating on Amylyx Pharmaceuticals with a $24 price target, citing strong financials and progress in avexitide's late-stage development for post-bariatric hypoglycemia. The company has $279.8M in cash, sufficient to fund operations into 2028, reducing financing risks. The pivotal Phase III LUCIDITY trial is expected to drive value, with a potential 2027 launch. Katkhuda has a 31.9% average return and a 54.36% success rate on his stock recommendations."
datetime: "2026-05-07T20:55:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285621003.md)
  - [en](https://longbridge.com/en/news/285621003.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285621003.md)
---

# Buy Rating Reiterated on Amylyx as Avexitide Progress and Cash Runway Support Upside vs. Unchanged $24 Price Target

In a report released today, Rami Katkhuda from LifeSci Capital maintained a Buy rating on Amylyx Pharmaceuticals Inc, with a price target of $24.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Rami Katkhuda has given his Buy rating due to a combination of factors, including Amylyx’s solid financial footing and the advancing late-stage development of avexitide for post-bariatric hypoglycemia (PBH). The company ended Q1 2026 with approximately $279.8M in cash and equivalents, which management believes is sufficient to fund operations into 2028, reducing near- to mid-term financing risk.

Katkhuda also points to the pivotal Phase III LUCIDITY trial of avexitide as a key value driver, noting that the study design is underpinned by strong mechanistic rationale and a robust body of prior PBH data that meaningfully de-risks the program. With a potential 2027 launch, ongoing regulatory preparations, expansion of commercial infrastructure, a new ICD-10 code to support disease recognition, and a promising early-stage GLP-1 antagonist candidate (AMX0138) progressing toward the clinic, he sees attractive upside relative to the unchanged $24 price target.

Katkhuda covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Viridian Therapeutics, and Disc Medicine. According to TipRanks, Katkhuda has an average return of 31.9% and a 54.36% success rate on recommended stocks.

In another report released on May 5, TD Cowen also maintained a Buy rating on the stock with a $0.00 price target.

### Related Stocks

- [AMLX.US](https://longbridge.com/en/quote/AMLX.US.md)
- [VRDN.US](https://longbridge.com/en/quote/VRDN.US.md)
- [IRON.US](https://longbridge.com/en/quote/IRON.US.md)

## Related News & Research

- [Amylyx Pharmaceuticals Eyes Phase 3 AVEXITIDE Readout as 2027 Launch Comes Into Focus](https://longbridge.com/en/news/286360144.md)
- [Amylyx Pharmaceuticals Inc (AMLX) Receives a Buy from Guggenheim](https://longbridge.com/en/news/285935233.md)
- [RBC Capital Sticks to Their Buy Rating for Brambles  (BMBLF)](https://longbridge.com/en/news/286848311.md)
- [Analyst Reaffirms Buy on Agilysys, Maintains $120 Price Target Amid Strong Growth and Margin Outlook](https://longbridge.com/en/news/286884474.md)
- [UnitedHealth Group Incorporated $UNH Holdings Boosted by GSA Capital Partners LLP](https://longbridge.com/en/news/286878927.md)